Oramed Pharmaceuticals Inc
ORMP
Company Profile
Business description
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
Contact
1185 Avenue of the Americas
Third Floor
New YorkNY10036
USAT: +1 844 967-2633
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
ASX retail share remains cheap despite weaker earnings
Weaker profit result drives cut to fair value yet shares remain undervalued.
stocks
AI isn’t an economic moat killer, but it will disrupt industries
How we’re rethinking companies’ competitive advantages in an AI-first world.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,741.70 | 16.80 | -0.19% |
| CAC 40 | 7,846.55 | 102.63 | 1.33% |
| DAX 40 | 22,957.08 | 320.17 | 1.41% |
| Dow JONES (US) | 46,429.49 | 305.43 | 0.66% |
| FTSE 100 | 10,106.84 | 141.68 | 1.42% |
| HKSE | 25,335.95 | 272.24 | 1.09% |
| NASDAQ | 21,929.82 | 167.93 | 0.77% |
| Nikkei 225 | 53,749.62 | 1,497.34 | 2.87% |
| NZX 50 Index | 13,050.98 | 121.68 | 0.94% |
| S&P 500 | 6,591.90 | 35.53 | 0.54% |
| S&P/ASX 200 | 8,537.00 | 10.00 | -0.12% |
| SSE Composite Index | 3,931.84 | 50.56 | 1.30% |